Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 22 of 1,261
  1. US 12384854

    Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

    Takeda Pharmaceutical Company Limited Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  2. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Protalix Ltd. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  3. US 12384829

    Pocket engineering of HLA alleles for treating autoimmunity

    The Regents of the University of Colorado, a Body Corporate Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  4. US 12384797

    Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

    PTC THERAPEUTICS, INC. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  5. US 12384779

    Bicyclic compounds

    Aligos Therapeutics, Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  6. US 12384753

    17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  7. US 12384775

    Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  8. US 12384845

    Activatable masked anti-CTLA4 binding proteins

    Xilio Development, Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  9. US 12384789

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  10. US 12384750

    Ras inhibitors

    Revolution Medicines, Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  11. US 12383626

    Polyoxazoline-drug conjugates with novel pharmacokinetic properties

    Serina Therapeutics (AL), Inc. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  12. US 12384761

    Imidazolo indazole compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  13. US 12383554

    Compositions and methods to protect mammalian tissue against cold and other metabolic stresses

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  14. US 12383512

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  15. US 12383566

    Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity

    Northwestern University Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  16. US 12383629

    DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  17. US 12383733

    Iontophoresis-based patch type medicine absorption device

    ROOTONIX Co., Ltd. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  18. US 12383631

    Immune antigen specific IL-18 immunocytokines and uses thereof

    Bright Peak Therapeutics AG Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  19. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  20. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Aug 12, 2025 Β· Expires Aug 7, 2045

    granted
  21. WO 2025165930

    MÉTHODES DE TRAITEMENT DE L'AMYOTROPHIE SPINALE

    BIOGEN MA INC [US] Β· Granted Aug 7, 2025 Β· Expires Aug 2, 2045

    granted
  22. US 2025250277

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] Β· Granted Aug 7, 2025 Β· Expires Aug 2, 2045

    granted
  23. US 12377102

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Galectin Sciences, LLC Β· Granted Aug 5, 2025 Β· Expires Jul 31, 2045

    granted
  24. US 12377096

    Methods of treating disease with levoketoconazole

    XERIS PHARMACEUTICALS, INC. Β· Granted Aug 5, 2025 Β· Expires Jul 31, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.